BioSpace News Archive

Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC).

Ilana Graetz, PhD, will serve as the special guest editor of the 9th annual health information technology (IT) issue of The American Journal of Managed Care® (AJMC®), which will be published in January 2020.

Mӧlnlycke® will celebrate the game-changing invention of Safetac® technology while focusing on continued innovations in wound care at WOCNext 2019 being held June 23-26 in Nashville, TN.

In the spirit of promoting public transparency, the U.S. Food and Drug Administration’s Center for Devices and Radiological Health is taking a number of important steps to update its Medical Device Reporting (MDR) Program

On June 11, 2019, the Society for Public Health Education sponsored a congressional briefing and panel discussion in celebration of the 20th Anniversary of the CDC’s Racial and Ethnic Approaches to Community Health (REACH) program